GW501516 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-23 and is reviewed periodically as new material appears.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
1993/150) Council Tax (Liability for Owners) (Amendment) Regulations 1993 (S.I. 1993/151) Genetically Modified Organisms (Deliberate Release) Regulationa 1993 (S.I. 1993/152) Barnsley Community and Priority Services National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/153) Mersey Regional Ambulance Service National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/154) North Mersey Community National Health Service Trust (Establishment) Amendment Order 1993 (S.I. 1993/155) Shropshire's Mental Health National Health Service Trust (Establishment) Amendment Order 1993 (S.I. 1993/156) Thameside Community Health Care National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/157) Drivers' Hours (Passenger and Goods Vehicles) (Exemption) (Revocation) Regulations 1993 (S.I. 1993/158) Manchester Central Hospitals and Community Care National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/159) A30 and A39 Trunk Roads (Indian Queens, Fraddon and St Columb Road Bypasses and Slip Roads) Order 1993 (S.I. 1993/163) A30 and A39 Trunk Roads (Indian Queens, Fraddon and St Columb Road Bypasses) (Detrunking) Order 1993 (S.I. 1993/164) General Drainage Charges (Relevant Quotient) Regulations 1993 (S.I. 1993/165) Central Rating Lists (Amendment) Regulations 1993 (S.I. 1993/166) Spring Traps Approval (Scotland) Variation Order 1993 (S.I. 1993/167) Humberside and South Yorkshire (County Boundaries) Order 1993 (S.I. 1993/168) Special Road Schemes and Highways Orders (Procedure) Regulations 1993 (S.I.
== Natural occurrence == DCA has been shown to occur in nature in at least one seaweed, Asparagopsis taxiformis and also in the mushroom Russula nigricans. It is a trace product of the chlorination of drinking water and is produced by the metabolism of various chlorine-containing drugs or chemicals. DCA is typically prepared by the reduction of trichloroacetic acid (TCA). DCA is prepared from chloral hydrate also by the reaction with calcium carbonate and sodium cyanide in water followed by acidifying with hydrochloric acid. As a laboratory reagent, both DCA and TCA are used as precipitants to prompt macromolecules such as proteins to precipitate out of solution.
== Overview == The ribosomal P-site plays a vital role in all phases of translation. Initiation involves recognition of the start codon (AUG) by initiator tRNA in the P-site, elongation involves passage of many elongator tRNAs through the P site, termination involves hydrolysis of the mature polypeptide from tRNA bound to the P-site, and ribosome recycling involves release of deacylated tRNA. Binding a tRNA to the P-site in the presence of mRNA establishes codon-anticodon interaction, and this interaction is important for small subunit ribosome (30S) contacts to the tRNA. The classical two-state model proposes that the ribosome contains two binding sites for tRNA, P-site and A-site. The A-site binds to incoming aminoacyl-tRNA which has the anti-codon for the corresponding codon in the mRNA presented in the A-site. After peptide formation between the C-terminal carbonyl group of the growing polypeptide chain (attached to a P-site bound tRNA) and the amino group of the aminoacyl-tRNA (A-site bound), the polypeptide chain is then attached to the tRNA in the A-site. The deacylated tRNA remains in the P-site and is released once the peptidyl-tRNA is transferred to the P-site. How is the translocation of the peptidyl-tRNA from the A-site to the P-site achieved to complete the cycle? It was proposed that this is done in two steps by the movement of the two ribosomal subunits with respect to each other, with the formation of an intermediate hybrid structure: the A-site of one subunit with the P-site of the other subunit.
Sources: en.wikipedia.org
== Pathology == Aflatoxin B1 can permeate through the skin. Dermal exposure to this aflatoxin in particular environmental conditions can lead to major health risks. The liver is the most susceptible organ to aflatoxin B1 toxicity. In animal studies, pathological lesions associated with aflatoxin B1 intoxication include reduction in weight of liver, vacuolation of hepatocytes, and hepatic carcinoma. Other liver lesions include enlargement of hepatic cells, fatty infiltration, necrosis, hemorrhage, fibrosis, regeneration of nodules, and bile duct proliferation/hyperplasia.
== Prognosis == The prognosis for individuals with Pompe disease varies according to the onset and severity of symptoms, along with lifestyle factors. Without treatment the infantile form (which can typically be predicted by mutation analysis) of the disease is particularly lethal — in these cases, the time taken to begin treatment is critical, with evidence that days (not weeks or months) matter. Myozyme (alglucosidase alfa) is a recombinant form of the human enzyme acid alpha-glucosidase, and is also currently being used to replace the missing enzyme. In a study which included the largest cohort of patients with Pompe disease treated with enzyme replacement therapy (ERT) to date findings showed that Myozyme treatment clearly prolongs ventilator-free survival and overall survival in patients with infantile-onset Pompe disease as compared to an untreated historical control population. Furthermore, the study demonstrated that initiation of ERT before six months of age, which could be facilitated by newborn screening, shows great promise to reduce the mortality and disability associated with this devastating disorder. Taiwan and several states in the United States have started newborn screening and results of such regimens in early diagnosis and early initiation of the therapy have dramatically improved the outcome of the disease; many of these babies have reached normal motor developmental milestones.
Early attempts to create alien-human hybrids were pioneered by German and Japanese scientists shortly after World War II, and for some time during the Cold War. However, these often met with failure, and the Syndicate started to rely more on their own scientists. According to the Alien Bounty Hunter, in the 1950s, Soviet geneticists found a unique genetic anomaly within identical twins. The Colonists and Syndicate scientists used this to eventually develop human clones with alien elements and partial hybrids, but they were still ultimately inferior. Hybrids of this type include Samantha Mulder, Kurt Crawford, the Gregors, Ernest Calderon, and Dr. William Secare. Child and adult versions of Samantha and Kurt are also seen. These clones have the same caustic greenish blood of the aliens, have greater muscular strength and higher physical endurance levels than most normal humans, and can breathe underwater. In addition to their intended use by the alien colonists, the Syndicate is occasionally seen using these clones to perform various tasks, such as research and physical labor. The pinnacle of the project is Cassandra Spender (Veronica Cartwright), mother of Jeffrey Spender (Chris Owens) and ex-wife of The Smoking Man. Cassandra is a hybrid created through a process other than cloning, and worked on by both the Syndicate and the aliens themselves, although the exact methods used to transform her are never fully revealed. The experiment presumably began when she, along with other family members of the Syndicate, were turned over to the colonists in 1973.
== Characterization == Volatile thiols are easily and almost unerringly detected by their distinctive odor. Sulfur-specific analyzers for gas chromatographs are useful. Spectroscopic indicators are the D2O-exchangeable SH signal in the 1H NMR spectrum (33S is NMR-active but signals for divalent sulfur are very broad and of little utility). The νSH band appears near 2400 cm−1 in the IR spectrum. In the nitroprusside reaction, free thiol groups react with sodium nitroprusside and ammonium hydroxide to give a red colour.
Sources: en.wikipedia.org
Materiel or matériel (; from French matériel 'equipment, hardware') is supplies, equipment, and weapons in military supply-chain management, and typically supplies and equipment in a commercial supply chain context.
== Ocean pollution == A Wall Street Journal report on ocean pollution, specifically, "Annual metric tonnes of mismanaged plastic waste in global waters", identified the top 12 polluting nations as of 2010. China was number one, Thailand at number seven, tied with Egypt. Five ASEAN nations were among the 12: Indonesia, 2; Philippines, 3; Vietnam, 4; Thailand, 7; Malaysia, 8.
The birds were a food and fuel source for early European settlers, and are now farmed, in Australia and elsewhere, for their meat, oil and leather. Commercial emu farming started in Western Australia around 1970. The commercial industry in the country is based on stock bred in captivity, and all states except Tasmania have licensing requirements to protect wild emus. Outside Australia, emus are farmed on a large scale in North America, with about 1 million birds in the US, Peru, and China, and to a lesser extent in some other countries. Emus breed well in captivity, and are kept in large open pens to avoid the leg and digestive problems that arise from inactivity. They are typically fed on grain supplemented by grazing, and are slaughtered at 15 to 18 months. The Salem district administration in India advised farmers in 2012 not to invest in the emu business which was being heavily promoted at the time; further investigation was needed to assess the profitability of farming the birds in India. In the United States, it was reported in 2013 that many ranchers had left the emu business; it was estimated that the number of growers had dropped from over five thousand in 1998 to one or two thousand in 2013. The remaining growers increasingly rely on sales of oil for their profit, although, leather, eggs, and meat are also sold.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.